Mayssa Attar
`Associate Vice President - Clinical Pharmacology, Metabolism and Immunology at Allergan
`
`Summary
`
`18+ years drug development experience in clinical pharmacology, pharmacokinetics, pharmacodynamics and
` drug metabolism. Diplomate of the American Board of Toxicology.
`
`Key roles in which I serve(d) include:
`•Clinical Pharmacology Head
`•Pharmacokinetics and Pharmacodynamics Head
`•Global Project Team Leader delivering a Phase 3 asset with >$1 billion/year commercial opportunity
`•Oversight of a >$80 million annual budget for a Phase 3 program
`•Adjunct Assistant Professor at the University of Southern California, School of Pharmacy.
`
`Major accomplishments include: 7 successive promotions with increasing scope of responsibility over 15 years,
` positioned PK/PD data to support regulatory strategy and gained additional patent protection for >billion dollar
` in sales product, negotiated and partnered with Emerging Market country’s Ministry of Health to present PK
` and safety data to reverse a government directive to support first marketing approvals, consistent performance
` in identifying and developing talent for the organization.
`
`Developed small and large molecule drugs and devices across multiple therapeutic areas including
` ophthalmology (inflammation, dry eye, glaucoma and retinal disease), CNS (neuropathic pain, migraine and
` movement disorders), urology, dermatology (acne, rosacea, hair growth) and medical aesthetics.
`
`Successfully serve as a liaison representing clinical pharmacology and nonclinical development to global health
` authorities/site inspectors, USPTO and KOLs to support business critical projects. Act as an expert witness
` to support litigation associated with intellectual property. Represent R&D during in-licensing and technology
` assessments in collaboration with legal and commercial colleagues. Participated in integration teams for
` mergers and acquisitions with experience representing the acquiring company and the acquired company.
`
`Experience
`Associate Vice President - Clinical Pharmacology, Metabolism and Immunology at Allergan
`January 1999 - Present
`Allergan Inc was acquired by Actavis plc in Mar 2015 and the new company adopted the name Allergan plc.
` In the new company, my scope of responsibility increased to include oversight of the ADME group and
` Immunology group in addition to my responsibility for oversight of the Clinical Pharmacology/PKPD group.
` I currently report to the R&D site head.
`
`Page 1
`
`MYLAN - EXHIBIT 1033
`Mylan Pharmaceuticals Inc. et al. v. Allergan, Inc.
`IPR2016-01127, -01128, -01129, -01130, -01131, & -01132
`
`

`

`Lead a team of scientists responsible for the integrated assessment of nonclinical through clinical
` Pharmacokinetics and Pharmacodynamics supporting Allergan's entire R&D portfolio. Member of the
` Nonclinical Development Leadership team that provides departmental strategic and operational oversight.
` Team member in organizational restructuring/change management efforts to improve departmental
` efficiencies.
`
`Final accountability for successful support of Allergan’s entire R&D portfolio through the strategic and
` technical oversight of clinical and nonclinical pharmacokinetic, drug metabolism, PK/PD modeling and
` simulation activities.
`
`Provide direction for identifying and developing talent to build technical capabilities (in silico, in vitro, in
` vivo and clinical PK/pharmacology) and strengthen project representation. Cross-functional team leader for
` early development through market launch teams.
`
`Serve as a lead representative when interacting with global regulatory agencies, health authority site
` inspectors, USPTO, KOLs, due diligence interactions, legal and commercial colleagues/activities.
`
`One of the original founders and team member for Allergan’s first “Accelerator/Incubator” drug development
` team.
`
`Received 7 successive promotions with increasing scope of responsibility over the past sixteen years.
` Associate Professional/Professional/Senior Professional/Scientist/Senior Scientist/Principal Scientist/
`Director/Senior Director.
`
`Adjunct Assistant Professor at University of Southern California
`December 2010 - Present
`Develop course materials, learning aids, exams and offer lectures on the subjects of Pharmacokinetics,
` Pharmacodynamics, Drug Metabolism and Pharmacogenomics.
`
`Mentor students as they consider careers in industry including acting as a mentor to PharmD and PhD
` fellows.
`
`Online Instructor at American College of Clinical Pharmacology
`2007 - 2014 (7 years 11 months)
`Served as an instructor for FDA/ACCP online course “Future of Medicine: Pharmacogenomics” Module 4,
` Drug Metabolism. Support for the course was provided by GlaxoSmithKline and Third Wave Technologies.
` Introductory Modules given by Gilbert J. Burckart ad Lawrence Lesko of FDA. http://news.usc.edu/17201/
`USC-School-of-Pharmacy-professor-helps-create-online-drug-monitoring-course/
`
`Page 2
`
`

`

`Research Associate at Ottawa Hospital Research Institute
`1995 - 1998 (3 years 11 months)
`
`Summer Intern at The Ottawa Hospital
`May 1994 - September 1994 (4 months)
`Cardiology Unit
`
`Education
`University of Southern California
`Doctor of Philosophy (Ph.D.), Pharmaceutical Sciences
`Activities and Societies: Rho Chi Society
`University of Ottawa
`Master’s Degree, Biochemistry
`University of Ottawa
`Bachelor’s Degree, Biochemistry
`
`Page 3
`
`

`

`Mayssa Attar
`Associate Vice President - Clinical Pharmacology, Metabolism and Immunology at Allergan
`
`Contact Mayssa on LinkedIn
`
`Page 4
`
`